Overview
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-09-01
2022-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.Phase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Nacuity Pharmaceuticals, Inc.
Criteria
Inclusion Criteria:1. Indicated for vitrectomy
2. Natural Lens in place at time of vitrectomy
3. Some cataract present as assessed pre-operatively
Exclusion Criteria:
1. Previous intraocular surgery in study eye
2. Clear zonular weakness or defects / coloboma
3. Not on stable dose of medications for other conditions.
4. Need for oral corticosteroids during study participation.
5. Evidence or history of diabetic retinopathy, glaucoma, uveitis, or ocular ischemia.
6. Current smoker
7. Use of supplemental oxygen
8. Diabetes
9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.
10. Sensitivity to thiol compounds.
11. Participation in another clinical trial.